{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:46:30Z","timestamp":1771047990650,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtct.2024.04.007","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:17:37Z","timestamp":1712902657000},"page":"750-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed\/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Hamza","family":"Hashmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-6694","authenticated-orcid":false,"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pashna N.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.04.007_bib0001","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.04.007_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2024.04.007_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.04.007_bib0004","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.007_bib0005","doi-asserted-by":"crossref","unstructured":"Hashmi H, Hansen DK, Peres LC, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024;109(5):1514--1524.https:\/\/doi.org\/10.3324\/haematol.2023.283888.","DOI":"10.3324\/haematol.2023.283888"},{"key":"10.1016\/j.jtct.2024.04.007_bib0006","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT Clinical Practice Recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.04.007_bib0007","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"173","article-title":"Post-CAR-T cell therapy (consolidation and relapse): multiple myeloma","author":"Rodr\u00edguez-Otero","year":"2022"},{"key":"10.1016\/j.jtct.2024.04.007_bib0008","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2024.04.007_bib0009","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2023-181762","article-title":"Real world outcomes with idecabtagene vicleucel (Ide-Cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"142","author":"Sidana","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.04.007_bib0010","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.04.007_bib0011","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/2643-3230.BCD-23-0134","article-title":"MRD and plasma cell dynamics after CAR T-cell therapy in myeloma","volume":"4","author":"Landgren","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2024.04.007_bib0012","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2024.04.007_bib0013","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2024.04.007_bib0014","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2024.04.007_bib0015","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2022-168903","article-title":"Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors","volume":"140","author":"Samur","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.04.007_bib0016","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2024.04.007_bib0017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.04.007_bib0018","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2024.04.007_bib0019","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.04.007_bib0020","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2024.04.007_bib0021","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.04.007_bib0022","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.04.007_bib0023","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA-directed CAR T-cell therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T15:31:07Z","timestamp":1723217467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724003476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2666636724003476"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed\/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}